SCHEMBL15569322

SCHEMBL15569322

O=C(CN1CCOCC1)N[C@@H](COC(F)F)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS11D O60235 1/20 0.51
CTRL P40313 1/20 0.51
PSMB5 P28074 10/20 0.51
PSMB8 P28062 9/20 0.51
PSMB9 P28065 4/20 0.51
PSMB1 P20618 2/20 0.51
PSMB10 P40306 2/20 0.51
PSMB2 P49721 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP3A5 P20815 2/20 0.51
CYP3A7 P24462 2/20 0.51
CYP3A43 Q9HB55 2/20 0.51
PSMB11 A5LHX3 1/20 0.51
PSMD11 O00231 1/20 0.51
PSMD12 O00232 1/20 0.51
PSMD14 O00487 1/20 0.51
PSMA7 O14818 1/20 0.51
PSMD3 O43242 1/20 0.51
CTSB P07858 1/20 0.51
PSMC3 P17980 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16970522 1.00 TMPRSS11D (0.51) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16970553 0.97 PSMB5 (0.52) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16910561 0.96 PSMB5 (0.53) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16970537 0.95 CTRL (0.59) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16970524 0.94 TMPRSS11D (0.61) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16984801 0.91 TMPRSS11D (0.49) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16924992 0.91 TMPRSS11D (0.49) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16984918 0.90 PSMB5 (0.51) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16970561 0.90 CTRL (0.55) TMPRSS11DCTRLPSMB5PSMB8PSMB9
SCHEMBL16925152 0.89 PSMB5 (0.52) TMPRSS11DCTRLPSMB5PSMB8PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160347792-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2016-12-01 US disclosed
US-20160347792-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2016-12-01 US disclosed
US-9441012-B2 Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors TRILLIUM THERAPEUTICS INC. (CA) 2016-09-13 US disclosed
US-9441012-B2 Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors TRILLIUM THERAPEUTICS INC. (CA) 2016-09-13 US disclosed
US-20150203534-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS FLUORINOV PHARMA INC. (CA) 2015-07-23 US disclosed
US-20150203534-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS FLUORINOV PHARMA INC. (CA) 2015-07-23 US disclosed
EP-2885314-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS Fluorinov Pharma Inc. (CA) 2015-06-24 EP disclosed
WO-2014026282-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS SLASSI ABDELMALIK (CA) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347792-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS PSMB5, PSMB1, PSMB7 TMPRSS11D 2545/4885CTRL 582/4885PSMB5 1/4885
US-20150203534-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS PSMB5, PSMB1, PSMB7 TMPRSS11D 2594/4885CTRL 670/4885PSMB5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.